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ABSTRACT
CANNABINOIDS SUPPRESS THE INNATE IMMUNE RESPONSE TO
THE PERIODONTAL PATHOGEN PORPHYROMONAS GINGIVALIS IN
GINGIVAL EPITHELIAL CELLS
By
Rajarshi Guha Niyogi
June 6 2016
Marijuana is widely used in the United States for recreational and
medicinal purposes. Despite the proposed beneficial effects of
cannabis on certain medical conditions, there is also a concern there is
also a concern over negative health consequences of marijuana
smoking. Recently, cannabis use has been established as a doserelated risk factor for chronic periodontitis. Although the induction /
exacerbation of chronic periodontitis in marijuana users has been
established epidemiologically, the mechanisms underlying such
predisposition are still unknown. It has long been suggested that
marijuana has anti-inflammatory properties, while human epithelial
cells are known to express cannabinoid receptor type 2 (CB2).
Therefore, we hypothesized that marijuana-derived cannabinoids may
suppress the innate immune response, altering the ability of gingival
epithelial cells to respond appropriately to bacterial stimuli (the
classic TLR4 ligand, E. coli LPS; and the major periodontal
vi

pathogen, Porphyromonas gingivalis). More specifically, we
hypothesized that predominant phytocannabinoid subtypes
(cannabidiol [CBD], cannabinol [CBN], or tetrahydrocannabinol
[THC]) at physiologically relevant doses (0 - 10µg/ml) would
suppress proinflammatory cytokine production in LPS- (0-1µg/ml) or
P. gingivalis (MOI, 10:1) exposed telomerase immortalized human
gingival keratinocytes (TIGK cells) in a CB2-related manner. We also
hypothesized that marijuana-derived cannabinoids may influence the
viability of both epithelial (TIGK cells, as assessed by Trypan blue
exclusion) and representative oral bacteria (P. gingivalis, Treponema
denticola and Filifactor alocis, growth curves monitored by optical
density). Higher doses (>5 µg/ml) of marijuana derived cannabinoids
(CBD, CBN or THC) inhibited the growth of P. gingivalis (p < 0.001)
and F. alocis (p < 0.001), relative to unexposed bacteria, whereas T.
denticola growth was resistant to all cannabinoid doses tested (1- 10
µg/ml, p > 0.05).. TIGK cells were non-viable when exposed to high
cannabinoid concentrations (> 10 µg/ml).Sub-lethal (1 -5 µg/ml)
doses of each cannabinoid subtype suppressed the production of IL-8
and IL-6 but enhanced IL-10 release in P. gingivalis or LPSstimulated TIGKs (all p < 0.001). Treatment with the CB2 inhibitor,
JTE907, did not rescue cannabinoid-induced immune suppression,
suggesting that alternative cannabinoid receptors, such as CB1,
GPR55 or A2A receptors, may be associated with the anti-
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inflammatory function of marijuana-derived cannabinoids. If the
phenomena of (i) cannabinoid induced epithelial toxicity; (ii) growth
restriction of a sub-population of bacterial species in the oral biofilm;
and (iii) innate suppression in gingival epithelial cells, established
herein, occur in vivo, they are likely to help explain increased
susceptibility to periodontal diseases in cannabis users. To expand,
the epithelial barrier may be compromised in marijuana smokers,
facilitating bacterial entry and more efficient diffusion of microbial
toxins into the gingival tissues; marijuana-derived cannabinoids may
promote microbial dysbiosis; and a suppressed pro-inflammatory
epithelial response to bacterial stimuli may promote immune evasion,
colonization and persistence by pathogenic bacteria. These data
provide some of the first mechanistic insights into cannabinoid
associated periodontal diseases. Such mechanistic advance are critical
if novel therapeutics to prevent chronic periodontitis in marijuana
users are to be developed. Further, an improved understanding of the
immuneregulatory properties of cannabinoids will be useful in the
development of therapeutics for the containment of inflammation, in
general
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CHRONIC PERIODONTITIS
Chronic periodontitis is an inflammatory condition affecting a large
section of the global adult population. It is a disease which affects the
supporting structures of the teeth causing marked degeneration and
destruction of these structures, potentially leading to the exfoliation of
the teeth. The host immune response plays a critical role in the
progression of chronic periodontitis. About 47.2% of the population
is affected by the disease and consumes $14 billion as health cost in
United States1, 2. Periodontitis is usually seen affecting the adult
population more although an acute aggressive variant is also noted in
young adults which is characterized by the extensive bone loss around
the lower incisors and first molars. Chronic periodontitis is
multifactorial disease and its progression depends on the interplay of
both intrinsic factors, like the immune response, and extrinsic
environmental factors, like smoking and oral hygiene habits3.

In humans, the epithelial layer of mucosal surface represents an initial
interface for colonizing microorganisms4. In addition to constituting a
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physical barrier to the entry of organisms, epithelial cells can sense
and respond to the presence of bacteria through an elaborate signaling
network that can communicate information to the underlying immune
effector cells5, 6. Environmental factors such as smoking can expose
the epithelial mucosa to numerous compounds which may
compromise these essential signaling pathways leading to a
suppressed innate response which predisposes to periodontal
pathogen infection, suppresses pathogen clearance, and increases
susceptibility to chronic periodontit
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IMMUNITY AND INFLAMMATION
Immunity is defined as the ability of the body to resist or fight off
infection and disease. Innate immunity, also known as the nonspecific
immune system, is the first line of defense8. It is a part of the overall
immune system that comprises the cells and mechanisms that defend
the host from infection by other organisms. This means that the cells
of the innate system recognize and respond to pathogens but do not
confer long-lasting or protective immunity to the host. Innate immune
systems provide immediate defense against infection6. The major
functions of the innate immune system include:
•

Recruiting immune cells to sites of infection, through the
production of chemical factors, including specialized chemical
mediators called cytokines.

•

Activation of the complement cascade to identify bacteria,
activate cells, and promote clearance of antibody complexes
or dead cells.
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•

The identification and removal of foreign substances present
in organs, tissues, the blood and lymph, by specialized white
blood cells.

•

Activation of the adaptive immune system through a process
known as antigen presentation.

•

Acting as a physical and chemical barrier to infectious agents.

Adaptive immunity on the other hand refers to antigen-specific
immune response. The adaptive immune response is more complex
than the innate. The antigen first must be processed and recognized.
Once an antigen has been recognized, the adaptive immune system
creates an army of immune cells specifically designed to attack that
antigen9.
Inflammation is part of the complex biological response of vascular
tissues to harmful stimuli such as pathogens, damaged cells and other
irritants. It is a protective response involving host cells, blood vessels,
proteins and other mediators that are intended to eliminate the initial
cause of cell injury and insult10. The classical signs of inflammation
are pain, heat, redness, swelling, and loss of function. Inflammation is
a stereotypical response, and therefore it is considered as a
mechanism of innate immunity as compared to adaptive immunity11,
which is specific for each path
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THE PERIODONTAL PATHOGEN - P. GINGIVALIS
The periodontal pathogen, P. gingivalis is an anaerobic, Gram negative
bacterium that is considered to be a major etiological factor in chronic
periodontitis12. It is a non-spore forming and belongs to the phylum
Bacteroidetes. This opportunistic pathogen is known to cause disease by
promoting shifts in the oral flora that lead to inflammation and bone loss13,
14

. P. gingivalis grows in vitro by forming smooth, raised colonies on

blood agar plates. The colonies appear creamy to white in color initially
and turn to black in three to four days with a specific unpleasant odor.
Bacterial colonies turn black due to the uptake of hemin from blood in the
plates15. Morphologically, the bacterium appears cocco-bacillar (small
rods) and is asacchrolytic and thus metabolizes the host proteins for its
growth and survival.
P. gingivalis have been considered as a “keystone” pathogen in
periodontal disease as it has a disproportionately large effect on its
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biofilm community when compared to its abundance16. The presence
of low numbers of P. gingivalis was required for the significant
increase in oral microbiota which was associated with disease(PSD
model)17 .The total percentage of abundance of P. gingivalis in few
cases was found to be less than 0.01% of oral commensal bacteria in
humans. The bacterium is also responsible for altering the normal
host-bacterial inter play in the periodontium18. It suppresses the
complement system and there by provides an excellent niche for other
commensal bacteria to grow and invade further, leading to
periodontitis.
The polysaccharide capsule is a potent virulence factor in P.
gingivalis. It has mechanisms that down-regulate specific aspects of
host immune response and thereby survives proficiently by masking
the host immune system19, 20.The capsule of P. gingivalis is thought to
make a

significant contribution to virulence of the bacterium. The

non-encapsulated strains would probably be less efficient in
progression of periodontitis due to their reduced ability of both
biofilm participation and tissue invasiveness21. It is indicated that the
capsule plays multiple roles in the virulence of P. gingivalis. These
include reduction of the host immune response to the bacterium,
reduced phagocytosis, and increased bacterial survival21, 22.
P.gingivalis has long been considered an important member of the
periodontopathic microbiota involved in periodontal disease
6

progression, bone and tissue destruction. P. gingivalis, because of its
ability to produce significant numbers of potential virulence
molecules, is considered an important pathogen in this progression
from health to disease23
P. gingivalis has two dominant kinds of fimbriae, major and minor.
The fimbriae play a critical part in the bacterial virulence. Six variants
of major fimbriae are known to exist depending on the genetic
diversity of the gene coding them (fim A). Type II fimbriae are
known to be associated with higher adhesion and invasive potential in
comparison to others. The minor fimbriae (mfa1) aid in cohesion with
other bacteria (Streptococcus gordonii) and thereby biofilm
development and growth24. The lipopolysaccharide (LPS) of P.
gingivalis is considered to be a potent virulence factor too. The LPS
stimulates the host inflammatory pathway by interacting with the
Toll-like Receptor 4 (TLR 4)25, 26. Interestingly, the LPS of P.
gingivalis exists in varying chemical structure, each with different
properties. The tetra-acylated form of LPS is a TLR 4 antagonist
whereas the penta-acylated form is a TLR 4 agonist. The shift from
penta-to tetra-acylated forms is regulated by the presence of hemin
(increased hemin levels up regulate tetra-acylation)27.
Gingipains are cysteine proteases that provide maximal advantage to
the bacterium in the exacerbation of periodontal disease. More than
85% of the proteolytic activity of the bacterium is accountable to the
7

existence of gingipains. These are encoded by three genes rgpA, rgpB
and kgp. rgpA and rgpB specifically cleave at arginine peptides and
kgp at lysine residue28. These play a multi-functional role in the
bacterium and are thereby considered vital for the survival of the
pathogen. rgpA is required for the maturation of long/major
fimbriae29. Thus, gingipains indirectly play a role in the attachment of
P. gingivalis in the biofilm. These proteases also enhance the
nonfimbrial adhesion mechanism by binding closely to epithelial
cells, fibroblasts and extra cellular matrix proteins including
fibrinogen, type V collagen, laminin and fibronectin. The destruction
of extra cellular matrix leading to progression of periodontitis is
attributed to gingipains30. Additionally, these proteolytic enzymes
help the bacterium in nutrient acquisition. Iron uptake by P. gingivalis
is attributed to the presence of hemagglutinins, which in turn are
regulated by gingipains31.
Furthermore, the bacterium also obtains peptides as a source of
carbon and nitrogen through gingipains. The gingipains, being
endonucleases, cleave the host proteins which are then converted to
di-tripeptides by the respective peptidases32. Finally, the di-tri
peptides are transported into the cell and then metabolized for energy
needs. Gingipains also neutralize and subvert the host immune
responses by cleaving several products in the pathway of complement
activation in the host33. Pathogenic strains of P. gingivalis are active
8

participants of the complex oral biofilms. Bacterial interactions
through quorum sensing, cross feeding, co-aggregation, contact
dependent signaling aid in the metabolic exchange, alteration of gene
expression and efficient survival of the organism in the biofilms34.
The interplay not only effectively improves the pathogenicity of P.
gingivalis but also of the entire communityThe initial colonization of
P. gingivalis in the oral cavity occurs by the adhesion to primary
colonizers, such as Streptococcus gordonii24. The minor fimbrial
antigen (mfa1) of P. gingivalis adheres to the streptococcal antigens I
and II. The interactions also aid in the survival of the bacteria in
adverse conditions. The ability of the bacterium to co-aggregate and
associate with several other bacteria in the biofilm, in turn up
regulates the virulence of the entire community17. P. gingivalis
invades several host cell types including gingival epithelial cells,
endothelial cells and smooth muscle cells35.
The inter-cellular spreading of P. gingivalis is through a unique
mechanism. The bacteria spread between the cells through actin based
membrane protrusions. This mode of inter-cellular translocation
prevents the bacterium from being exposed to the host’s immune
responses. Studies on the invasion process have suggested the
presence of a unique mechanism of invasion into the host. The serine
phosphatase enzyme of P. gingivalis is involved in this process. The
enzyme activity leads to dephosphorylation and activation of cofilin,
9

a protein responsible for actin remodeling through de
polymerization36. Although the bacterium can spread without cell-tocell contact, the tight cell contact hastens the invasion process. P.
gingivalis establishes a long term cohabitation with gingival epithelial
cells, which in turn can survive up to eight days after infection with
the bacteria37. Inside the cell, the bacteria migrate to the perinuclear
area and accumulate. The bacterium resides in the host cells,
overcoming the major challenges like oxidative stres
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OTHER REPRESENTATIVE PERIODONTAL PATHOGENS
$WDPLFURELDOOHYHOWKHRWKHUEDFWHULDPRVWFRPPRQO\DVVRFLDWHGZLWK
FKURQLFSHULRGRQWLWLVDUH7UHSRQHPDGHQWLFROD 7G 2UDOVSLURFKHWHV
RFFXS\DXQLTXHQLFKHLQWHUPVRIHQYLURQPHQWDQGWKHLUSRO\PLFURELDO
QDWXUH7UHSRQHPHVSRVVHVVDZLGHUDQJHRIYLUXOHQFHIDFWRUVWKDW
SURPRWHVXUYLYDODQGSDWKRJHQLFLW\LQWKHJLQJLYDOSRFNHW5HFHQW
H[DPSOHVRIPRELOH'1$HOHPHQWVJHQHWLFH[FKDQJHDQGEDFWHULRSKDJHV
KLJKOLJKWWKHFRPSOH[LW\RILQWHUDFWLRQVEHWZHHQRUJDQLVPVLQWKHRUDO
FDYLW\5HFHQWUHVHDUFKKDVDOVRIRFXVHGRQKRZRUDO7UHSRQHPHVVHQVH
DQGUHVSRQGWRWKHG\QDPLFHQYLURQPHQWV7KH\KDYHPXOWLSOH7&6VDQG
FKHPRWD[LVVHQVLQJUHFHSWRUVDQGPD\UHVSRQGE\ORFRPRWLRQDQG
YLUXOHQFHH[SUHVVLRQ7KH\DOVRH[SUHVVPXOWLSOHXSWDNHDQGUHJXODWRU\
V\VWHPVIRUQXWULHQWDFTXLVLWLRQ2UDOVSLURFKHWHVDIIHFWPXOWLSOHKRVWFHOO
W\SHV1RWDEO\WKH\FDQDFWLYDWHLPPXQHUHVSRQVHVOHDGLQJWRWLVVXH
LQMXU\EXWLPSDLUVRPHFUXFLDOLQQDWHUHVSRQVHVLQFOXGLQJQHXWURSKLO
IXQFWLRQDQG7/5DFWLYDWLRQSUHYHQWLQJWKHLURZQHUDGLFDWLRQ)LQDOO\
RUDO7UHSRQHPHVKDYHPDQ\FRQVHUYHGDVZHOODVVRPHXQLTXHYLUXOHQFH
SURSHUWLHV
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The other fast emerging periodontal pathogen is F. alocis41. F. alocis
is one of a few bacteria that is associated with multiple oral diseases
including periodontitis, localized aggressive periodontitis,
endodontitis and peri-implantitis. Its relative abundance in the
periodontal pocket of patients with periodontitis may support the
hypothesis to include F. alocis as a diagnostic marker organism42.
This organism has unique potential virulence characteristics such as
resistance to oxidative stress and genes coding for a well-developed
amino acid metabolic pathway that can modulate multiple changes to
the oral microbial community and the host cell proteome that
collectively can lead to the disease process43. Multiple studies have
documented the increasing incidence and importance of F. alocis ( In
comparison to the other traditional periodontal pathogens, the high
incidence of F. alocis in the1 periodontal pocket compared to its
absence in healthy or periodontitis resistant patients has highlighted
its importance in the infectious disease process. F. alocis has also
been discovered in the canals of root-filled teeth with periapical
lesions and is associated with signs and symptoms of endodontic
infections44. It has also been identified as one of the prevalent
phylotypes in cases of failed endodontic treatment. P. gingivalis
ATCC 33277 co-cultured with F. alocis showed significant increase
in biofilm formation. This enhanced biofilm forming capacity may be
due to the ability of both species to auto aggregate and express unique
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components. This could indicate a commensal relationship between
F. alocis and P. gingivalis. Thus, F. alocis and P. gingivalis, each
with different growth rates, could form a mixed species biofilm and
coexist. As a result, F. alocis proteins could enable P. gingivalis to
proliferate and disseminate from these biofilms thus facilitating its
virulence45.

13

CANNABINOIDS:
Cannabis, commonly known as marijuana, is a product of the Cannabis sativa
plant and the active compounds from this plant are collectively referred to as
cannabinoids46. Cannabinoids are a group of compounds that mediate their
effects through cannabinoid receptors. The discovery of
Δ9tetrahydrocannabinol (THC) as the major psychoactive principle in
marijuana, as well as the identification of cannabinoid receptors and their
endogenous ligands, has led to a significant growth in research aimed at
understanding the physiological functions of cannabinoids47. Cannabinoid
receptors include CB1, which is predominantly expressed in the brain and
mediates the psychotropic side effects, and CB2, which is primarily found on
the cells of the immune system48. Other sub-types of cannabinoids include
cannabidiol (CBD) and cannabinol (CBN). The fact that both CB1 and CB2
receptors have been found on immune cells suggests that cannabinoids could
play an important role in the regulation of the immune system49.
Cannabinoids are potent anti-inflammatory agents and they exert their effects
through suppression of cytokine production, inflammatory cell migration, and
induction of T-regulatory cells and induction of apoptosis50.
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The various mechanisms through which cannabinoids bring about
anti-inflammatory action are as follows:
A) CANNABINOIDS MODULATE CYTOKINE PRODUCTION:
Cytokines are the signaling proteins synthesized and secreted by
immune cells upon stimulation. They are the modulating factors
that balance initiation and resolution of inflammation. One of the
possible mechanisms of immune control by cannabinoids during
inflammation is the dysregulation of cytokine production by
immune cells51, 52. Furthermore, cannabinoids may affect immune
responses and host resistance by perturbing the balance between
the cytokines produced by T- helper subsets, Th1 and Th227.
Earlier studies have showed that THC have produced a
concentration-dependent inhibition of T cell proliferation53. The
production of cytokines by stimulated T cells plays a critical role
in amplifying and targeting immunity. When activated T cells
mature into Th1 cells, they secrete IL-2 and IFN-α and potentiate
cell-mediated immunity by enhancing T cell proliferation and
effector functions, up-regulating MHC expression, promoting
IgG2a isotype switching, and activating effector cells such as NK
cells and macrophages. In contrast, when activated T cells acquire
a Th2 phenotype, they secrete IL-4, IL-5 and/or IL-10, and
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potentiate allergic/atopic antibody responses while suppressing T
cell proliferation and cell mediated immunity53.
B) CANNABINOIDS MODULATE INFLAMMATORY-CELL
MIGRATION:
The accumulation of leukocytes in tissues contributes to a wide
variety of diseases; these 'molecular codes' have provided new targets
for inhibiting tissue-specific inflammation. However, immune cell
migration is also critically important for the delivery of protective
immune responses to tissues. Thus, the challenge for the future will
be to identify the trafficking molecules that will most specifically
inhibit the key subsets of cells that drive disease processes without
affecting the migration and function of leukocytes required for
protective immunity. Inflammatory migration of immune cells is
involved in many human diseases. Identification of molecular
pathways and modulators controlling inflammatory migration could
lead to therapeutic strategies for treating human inflammationassociated diseases. Although the exact mechanism is unknown but
studies have highlighted several signaling pathways that may
suppress the leukocyte inflammatory migration. Cannabinoids have
been found to suppress inflammatory cell migration in some studies
but exact mechanism still needs to be established. Few possible
mechanism through which cannabinoids can suppress inflammatory
cell migration through CB2 receptor are as follows:
16

• One of the studies have shown that CB2 receptor agonist have an
inhibitory action on the JNK/c-Jun/Alox5 Pathway54. The cooperative
effect between the Cnr2 agonist and the Alox5 inhibitor of leukocyte
inflammatory migration implicates a new strategy for developing
anti-inflammation therapies. Investigating the effect of a combined
therapy with Cnr2 agonist and Alox5 inhibitor would be valuable in
treating human diseases such as multiple sclerosis, rheumatoid
arthritis, atherosclerosis, asthma, or even cancer.
• It has also been seen that cannabinoid receptor 2 agonist reduces
immune cell migration in neuro inflammation via inhibition of matrix
metalloproteinase-955 .The study was done using murine model and
dendritic cell to conduct migration assay and see the effect of
cannabinoids on the migration of these cells were studied. The
Cannabinoid mediated suppression of leukocyte adhesion and
migration resulting from an inhibition of TH1cell cytokine
production.

C)

CANNABINOIDS REGULATE HELPER T CELLS:
Cannabinoids have a Th-cell biasing effect, in which Th1-cell
activity is suppressed and Th2-cell activity is increased56.
From prior studies, it seems that cannabinoids bias the
immune response away from Th1-cell immunity and that
cannabinoid receptors are involved in this process30.
17

Treatment with cannabinoids has been shown to alter the
expression of specific transcription factors, the expression of
the Th2-cellpromoting transcription factor GATA-binding
protein 3 (GATA3) has been found to be increased by
treatment with cannabinoids whereas the production of IL-2
expression-promoting transcription factors is suppressed by
treatment with cannabinoids. The selective suppression of
Th1-cell immunity by these drugs supports their potential use
in the treatment of chronic inflammatory diseases. There is
now ample evidence that cannabinoids and other GPCR
agonists can modulate the development of Th cells. In the case
of cannabinoids, it is possible that CB1 and CB2 may be
differentially expressed on different subpopulations of APCs
and Th cells57. This selective expression could lead to an
increase in Th2 development and a decrease in the
development of Th1 cells, resulting in suppression of innate
immunity and increased adaptive immunity49. Continued
research on the distribution and function of cannabinoid
receptors as well as the production of endocannabinoids by
different immune cells will provide greater insight into these
mechanisms. One of the objective of the future studies should
be not only to evaluate the therapeutic potential of
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cannabinoids but also innate immune suppression brought
about through cell biasing
D)

CANNABINOIDS HAVE AN APOPTOTIC EFFECTS ON
IMMUNE CELL

POPULATIONS: One major mechanism of immune suppression by
cannabinoids is the induction of cell death or apoptosis50. Apoptosis
is defined as the programmed cell death caused by both intrinsic and
extrinsic factors. Apoptosis eliminates damaged, harmful and
unwanted cells, it is significant in biological processes including
development, morphogenesis, and homeostasis. During apoptosis,
many morphological changes occur such as membrane blebbing, cell
shrinkage, mitochondria leakage, and nuclear fragmentation.
Molecular changes underlie these morphological changes, and they
make up the two different pathways of apoptosis: (1) intrinsic
pathway – via mitochondria, and (2) extrinsic pathway – through
death receptors.
Cannabinoids shows a wide range of apoptotic effect on different
types of immune cells like B cells, T cells, antigen presenting cells
like (Dendritic cells) and the malignant immune cells. In T cells prior
studies have shown suppression of T cell proliferation. The
endogenous cannabinoids have shown to induce apoptosis in the T
cell culture. This was mostly bought about by the BCl-2 and the
caspase activity. Systemic administration of THC has shown
19

suppressed proliferation of B cells, T cells and macrophages in
spleen. CBD has shown apoptosis of CD4/ and CD8/ in a time and
dose dependent manner.
Although the knowledge about the cannabinoids and their effect
on innate response in gingival epithelial cells in context to oral cavity
is limited. Few prior studies have shown that cannabinoid receptors
especially CB1 play an important role in suppressing innate immunity
through the TLR pathways utilizing the endocannabinoid ligands58.
Studies have also shown consistent expression of CB2 receptors in
the gingival epithelial cells and the periodontal ligament cells59,
60

.Multiple studies have established marijuana as an important risk

factor for chronic periodontitis in humans61, 62. Moreover marijuana
use appears to predispose teenagers and young adults to alveolar bone
and attachment loss63. Animal model studies have shown that
cannabinoids also predispose animals to destructive periodontal
disease. Rodents with ligated teeth exposed to marijuana smoke for
only eight mins per day develop more extensive alveolar bone loss
than ligated, unexposed animals64, while reduced bone healing around
implants has also been demonstrated in animals65.
In conclusion we see that activation of CB2 may have an antiinflammatory and anti-resorptive effects on LPS and P. gingivalisstimulated TIGK cells. These findings suggest that activation of CB2
might be an effective therapeutic strategy for the treatment of
20

inflammation and alveolar bone resorption in periodontitis. Our study
provides a potential rationale for the use of exogenous factors such as
CB2-specific agonists as drugs in the treatment of periodontitis.
Further studies are required to corroborate the effect of CB2
activation on periodontitis in vivo.
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TELOMERASE IMMORTALIZED GINGIVAL KERATINOCYTES
(TIGKS)
Gingival keratinocytes are used in model systems to investigate the
interaction between periodontal bacteria and the epithelium in the
initial stages of the periodontal disease process. The gingival
epithelium usually classified into sulcular epithelium, junctional
epithelium (nonkeratinized) and oral gingival epithelium
(keratinized). The junctional epithelium lies in the sulcus between the
soft and hard tissues and has a unique structure. The junctional
epithelium has intercellular spaces that create spaces for the immune
cells to migrate into the gingival sulcus. They are the first to
encounter the colonizing bacteria in the oral cavity and are thereby,
wellknown to play an important role in the host bacterial
environment. Several studies have shown the immunological
modulation brought about by the epithelial cells the first line of
defense is essential for the initiation and progression of periodontitis.
Primary gingival epithelial cells have their limitations. Primary
gingival epithelial cells are obtained from the gingival tissue of
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healthy human subjects and then isolated and cultured in the
laboratory .Primary gingival epithelial cells have been used as model
systems for several studies. However, the cells have a finite lifespan
and cease to grow after nine passages approximately and are then
challenged to senescence and stop replicating any further. The limited
life span poses a huge disadvantage in their usage. Also, there can be
dissimilarities in their phenotype from donor to donor, questioning
their use in in vitro experiments. To overcome the issue of finite life
span, epithelial cells immortalized with viral proteins also known as
the telomerase-immortalized human gingival epithelial cell line
exhibited the capacity to undergo several passages. Thus a cell line
which was comparable to the in vitro behavior of human GEC was
developed66.
Thus, we can summarize that with the literature supporting the use of
cannabis as a potent anti-inflammatory agent over several decades in
chronic inflammatory conditions, it would be interesting to find out
the nature and extent of cannabinoid-induced immune suppression in
epithelial cells and determine the mechanistic basis for this effect.
While clearly relevant to periodontal disease, such innate suppression
is likely to be a central mediator of inflammation per se and, thus,
have implications far beyond the oral cavity.
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CHAPTER 2: MATERIALS AND METHODS
BACTERIAL CULTURE
Porphyromonas gingivalis ATCC 33277, Filifactor alocis ATCC
35896 and Treponema denticola ATCC 35405 were purchased from
the American Type Culture Collection (Manassas, VA) and
maintained as frozen stocks. P. gingivalis was grown in Gifu
anaerobic medium (GAM; Nissui Pharmaceutical, Tokyo, Japan). F.
alocis was grown in brain heart infusion (BHI) medium (Becton
Dickinson, Sparks, MD) supplemented with L-cysteine (0.1%) and
arginine (20%, both Sigma-Aldrich, St. Louis, MO). T. denticola was
grown in tryptone-yeast extract-gelatin-volatile fatty acid-heat
inactivated rabbit serum (TYGVS) medium. A broth medium had the
following composition (per liter): tryptone (Difco Laboratories,
Detroit, Mich.), 10.0 g; brain heart infusion broth, 5.0 g; yeast extract,
10.0 g; gelatin, 10.0 g; (NH4)2SO4, 0.5 g; MgSO4- 7H2O, 0.1 g;
K2HPO4, 1.13 g; KH2PO4, 0.9 g; and NaCl, 1.0 g (TYGVS
medium). The pH was adjusted to 7.2 with 4 N KOH before the
autoclaving of the medium. The following ingredients were mixed,
neutralized with KOH, sterilized by filtration, and added aseptically
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to the autoclaved medium containing (final concentration, per liter):
glucose, 1.0 g; cysteine hydrochloride, 1.0 g; thiamine
pyrophosphate, 0.0125 g; sodium pyruvate, 0.25 g; acetic acid, 0.27
ml; propionic acid, 0.10 ml; n-butyric acid, 0.064 ml; n-valeric acid,
0.016 ml; isobutyric acid, 0.016 ml; isovaleric acid, 0.016 ml; DLmethylbutyric acid, 0.016 ml; and heat-inactivated rabbit serum, 10%
(vol/vol). P. gingivalis, F. alocis, and T. denticola were grown under
anaerobic conditions (80% N2, 10% H2, and 10% CO2) at 370c.
Growth was monitored by tracking optical density at a wavelength of
600 nm. T. denticola ASLM, which had been isolated from human
subgingival plaque, was maintained and grown at 34°C in an
atmosphere of 85% N2, 10% H2, and 5% CO2 in an anaerobic
chamber (Coy Manufacturing, Ann Arbor, Mich.) in a broth medium
which had the following composition (per liter): tryptone (Difco
Laboratories, Detroit, Mich.), 10.0 g; brain heart infusion broth, 5.0 g;
yeast extract, 10.0 g; gelatin, 10.0 g; (NH4)2SO4, 0.5 g; MgSO47H2O, 0.1 g; K2HPO4, 1.13 g; KH2PO4, 0.9 g; and NaCl, 1.0 g
(TYGVS medium). The pH was adjusted to 7.2 with 4 N KOH before
the autoclaving of the medium. The following ingredients were
mixed, neutralized with KOH, sterilized by filtration, and added
aseptically to the autoclaved medium containing (final concentration,
per liter): glucose, 1.0 g; cysteine hydrochloride, 1.0 g; thiamine
pyrophosphate, 0.0125 g; sodium pyruvate, 0.25 g; acetic acid, 0.27
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ml; propionic acid, 0.10 ml; n-butyric acid, 0.064 ml; n-valeric acid,
0.016 ml; isobutyric acid, 0.016 ml; isovaleric acid, 0.016 ml;
DLmethylbutyric acid, 0.016 ml; and heat-inactivated rabbit serum,
10% (vol/vol).
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CELL CULTURE
Telomerase immortalized gingival keratinocytes (TIGKs) were
maintained as frozen stocks and cultured in Dermalife-K serum free
keratinocyte culture medium (Lifeline cell technology, Walkersville,
MD) containing the supplements, transferrin 5ug/ml, rh TGF-α
0.5ng/ml, rh insulin 5ug/ml, epinephrine 1.0uM, L- glutamine 6mM,
hydrocortisone 100ng/ml and extract-P 0.4%66. Cells were grown in a
humidified chamber at 37°C, 5% CO2. Medium was changed every 23 days and cells were passaged when 80-90% confluent. Cells were
passaged by washing twice with phosphate-buffered saline (PBS) and
incubating with 0.05%Trypsin/0.53mM EDTA at 37°C for 5-10
minutes until cells lifted from the surface of the flask. Dermalife-K
serum free keratinocyte culture medium was added to the cell
suspension to inhibit the enzymatic activity of trypsin/EDTA, and
cells were centrifuged at 9.7 g for 10 minutes. The supernatants were
removed, the cell pellet re-suspended in medium and re-seeded at 1.0
x 106 cells/T75 flask. The cells were seeded into 6well plates at 30%
confluence and infected when 80% confluence was attained (approx.
1.0 x 106 cells/well).

27

CYTOKINE EXPRESSIONS PATTERNS IN GINGIVAL EPITHELIAL
CELLS
TIGK cells were exposed, or not, to three cannabinoid subtypes
[cannabidiol, cannabinol, or tetrahydrocannabinol; 1, 5 or 10 µg /ml]
and epithelial viability was determined using the Trypan blue
exclusion test. TIGKs (1 x 106 cells per well) were also challenged, or
not, with P. gingivalis at MOI of 10 in the presence or absence of
cannabinoids [cannabidiol, cannabinol, or tetrahydrocannabinol; 0, 1,
or 5 µg /ml]. Bacterial cells were harvested at mid to late log phase.
Cytokine (IL-6, IL-8 and IL-10) induction and release was
determined by ELISA, according to the manufacturer’s instructions.
TIGKs (1 x 106 cells per well) were also challenged with LPS at
concentration of 1ug/ml in the presence or absence of cannabinoids
[cannabidiol, cannabinol, or tetrahydrocannabinol; 0, 1, or 5 µg /ml].
Cytokine (IL-6, IL-8 and IL-10) induction and release was again
determined by ELISA, according to the manufacturer’s instructions.
To check for the functional significance of the CB2 receptor, a CB2specific pharmacological inhibitor, JTE907 (Tocris, Bioscience), was
used at concentration of 5 µg/ml. Cells were exposed for 30 min to
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the inhibitor then exposed to cannabinoid subtypes for 2 hours and
then exposed to of bacterial stimulant LPS 1ug/ml and P. gingivalis at
MOI of 10:1 and incubated overnight. Twenty hour cell-free
supernatants were collected by centrifugation at 9.7 x g for 4 mins.
All experiments were performed in triplicate.
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STATISTICAL ANALYSIS
Statistical analyses were performed using Graph Pad Prism 6 (Graph
Pad Software, San Diego, CA). Data are presented as mean, standard
deviation of the mean (SD). Differences were analyzed with one-way
ANOVA and Student t test, as appropriate. Statistical significance
was set at p < 0.05.
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&+$37(5RESULTS
3.1 Cannabinoids, P. gingivalis and TIGK cell viability
HIGH CONCENTRATIONS OF CANNABINOIDS ARELETHAL TO TIGK CELLS
To investigate the influence of three archetypal cannabinoids on
TIGK viability, we exposed TIGK cells to various concentrations of
cannabidiol, cannabinol and tetrahydrocannabinol. As shown in
Figure 1, each cannabinoid subtype significantly lowered TIGK
viability at concentrations of 10 µg/ml, as determined by Trypan blue
exclusion. However, TIGK viability was not influenced by
cannabinoid concentrations of 5 µg/ml or less.

Figure 1A

Figure 1B

Figure 1C
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FIGURE 1: Viability of cannabinoid-exposed TIGK cells.

TIGK viability following exposure to (A) CBD, (B) CBN or (C) THC, at the
cannabinoid

concentrations noted, was determined by Trypan blue

exclusion.
*** p < 0.001 compared to the untreated control.
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P. gingivalis DOESNOT ALTER VIABILITY OF
CANNABINOID EXPOSED TIGK CELLS

The viability of cannabinoid-exposed and control TIGKs were also
monitored in presence and absence of P. gingivalis (MOI 10:1),
again, by Trypan blue cell exclusion assay. The data presented in
Figure 2 confirm that each cannabinoid subtype significantly
suppressed TIGK viability at concentrations of 10 µg/ml, while TIGK
viability was not influenced by cannabinoid concentrations of 5 µg/ml
or less. P. gingivalis did not influence TIGK viability in the presence
or absence of cannabinoids. Therefore, 0-5 µg/ml cannabinoid dosing
regimens and bacterial infections at MOI 10:1 were employed in the
remainder of the experiments.

Figure 2A

Figure 2B
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Figure 2C

FIGURE 2: P. gingivalis does not influence the viability of
cannabinoid-exposed TIGK cells.
TIGK viability following exposure to CBD, CBN or THC at (A) 1
µg/ml, (B) 5 µg/ml or (C) 10 µg/ml, was determined by Trypan blue
exclusion. P. gingivalis did not influence the viability of
cannabinoid-exposed TIGK cells (all, p > 0.05 compared to the
untreated control.
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3.2 Cannabinoid subtypes and the production of pro-inflammatory
cytokines in LPS & P. gingivalis-stimulated TIGK cells.
CANNABINOIDS SUPPRESS THE PRODUCTION OF IL-8 IN LPS & P.
gingivalis-STIMULATED TIGK CELLS
Bacterial lipopolysaccharides (LPS) are major outer surface
membrane components present in almost all Gram-negative
bacteria67. The lipid A portion of LPS is a potent stimulator of innate
immunity67, 68. Escherichia coli-derived LPS represents the classic
TLR4-dependent proinflammatory agonist68, 69. IL-8 is a major proinflammatory chemokine that is released by epithelial cells that have
detected microbial signals that, among other functions, acts as a
chemoattractant to immune cells, particularly neutrophils70, 71. P.
gingivalis is a major periodontal pathogen72. It causes perturbation of
the epithelial cells, invades the periodontal tissue and evades host
defense mechanisms72. In doing so, it utilizes its panel of virulence
factors causing deregulation of the innate immune response and
inflammatory process72, 73. P. gingivalis exists commensally in the
host and causes a dysbiotic shift of the microbial environment during
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the disease episodes17. It triggers a wide array of changes in the
gingival epithelial cells such as selective inhibition of certain immune
mediators and modulation of signaling pathways causing

dysregulation of innate immune response74. To check the influence of
marijuana derived cannabinoid subtypes on the release of IL-8, we
exposed TIGK cells to cannabinoid subtypes followed by LPS or P.
gingivalis. As shown in Figure 3, cannabinoids (CBD, CBN or THC;
1 and 5 µg / ml) significantly inhibited the LPS and P. gingivalisinduced IL-8 response in TIGK cells.

Figure3A
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Figure 3B
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FIGURE 3: Cannabinoids suppress IL-8 release in LPS & P. gingivalis-stimulated
TIGK cells. (A) CBD, (B) CBN or (C) THC, at the concentrations noted, suppressed IL8 release in LPS (1µg/ml)-stimulated TIGK cells, as determined in 20 hr cell-free
supernatants by ELISA. TIGK cells were exposed to cannabinoid subtypes (1 &
5µg/ml) for 2 hr. followed by addition of LPS (0-1µg/ml) or P. gingivalis [MOI 10:1]
for 18 hr. Figure 3, shows stats significant variation from P. gingivalis above, however
LPS also shows significant difference from all points on the graph except for
CBD1ug/ml +LPS (1µg/ml) & P. gingivalis alone (Figure3A); P. gingivalis alone
(Figure 3B). */ *** p < 0.5 / 0.001, respectively, compared to the P. gingivalis control.
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CANNABINOIDS SUPPRESS PRODUCTION OF IL-6 IN IN LPS & P.
gingivalis- STIMULATED TIGK CELLS
Periodontal pathogens and bacterial-derived stimulants, including
LPS, initiate pro-inflammatory changes in the periodontium cytokine
production75, 76.In the gingiva, IL-6 is produced by mononuclear cells.
These Macrophages were shown to secrete IL-6 in response to LPS in
a dosedependent manner77. The association between IL-6 and alveolar
bone loss in periodontal disease was also established in animal
models78. IL-6, synergistic with other inflammatory cytokine induces
bone resorption78, 79. Having established that cannabinoids suppress
the IL-8 response of TIGK cells, we next examined the influence of
CBD, CBN and THC on LPS or P. gingivalisinduced secretion of IL6 from TIGK cells. As shown in Figure 4, cannabinoids, (CBD, CBN
or THC; 1 and 5 µg / ml) significantly inhibited the LPS & P.
gingivalis-induced IL-6 response in TIGK cells in a similar manner to
IL-8.
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FIGURE 4: Cannabinoids suppress IL-6 release in LPS & P. gingivalisstimulated TIGK cells.(A) CBD, (B) CBN or (C) THC, at the concentrations
noted, suppressed IL-6 release in LPS (1µg/ml)-stimulated TIGK cells, as
determined in 20 hr cell-free supernatants by ELISA.TIGK cells were exposed

3.3 Cannabinoid subtypes and the production of the anti-

to marijuana derived cannabinoid subtypes at (1 & 5µg/ml) for 2hr , followed by
LPS(0-1µg/ml) or P. gingivalis [MOI 10:1] for 18hr. Figure 4, shows stats
significant variation from P. gingivalis above, however LPS also shows
significant difference from all points on the graph except for P. gingivalis
alone(Figure 4A); CBN 1µg/ml and P. gingivalis alone (Figure 4B);
THC1µg/ml + LPS (1µg/ml) (Figure 4C).**/ *** p < 0.01 / 0.001, respectively,
compared to the P. gingivalis control.
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Inflammatory cytokine ,IL-10, in LPS & P. gingivalis-stimulated
TIGK cells
CANNABINOIDS ENHANCE THE PRODUCTION OF IL-10 IN IN
LPS & P. gingivalis STIMULATED TIGK CELLS
Bacterial stimuli-induced cytokines play a major role in the
progression of chronic periodontitis80. Earlier, we considered the proinflammatory cytokines, IL-6 and IL-8. However, it is the balance of
pro- and anti-inflammatory mediators that determine the severity,
duration and direction of innate responses81. IL-10 is a key antiinflammatory cytokine that has been shown to have osteoprotective
properties82. P. gingivalis is known to be a major periodontal
pathogen associated with chronic periodontitis. IL-10 is an antiinflammatory cytokine known to have an important function in
balancing the effects of the pro-inflammatory cytokines, thus
modulating the progression of the chronic inflammation and
exacerbation of the disease state81. Therefore, we next determined the
influence of marijuana derived cannabinoid subtypes on the release of
IL-10 from LPS and P. gingivalis-stimulated TIGK cells. As shown
in Figure 5 cannabinoids (CBD, CBN or THC; 1 and 5 µg / ml)
significantly enhanced the LPS and P. gingivalis induced IL-10
response in TIGK cells.
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Figure 5A

Figure 5B

Figure 5C
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FIGURE 5: Cannabinoids enhance IL-10 release in LPS & P. gingivalisstimulated TIGK cells.
(A) CBD, (B) CBN or (C) THC, at the concentrations noted, enhanced IL-10
release in LPS (1µg/ml)-stimulated TIGK cells, as determined in 20 hr cell-free
supernatants by ELISA. TIGK cells were exposed to marijuana derived
cannabinoid subtypes at (1 & 5µg/ml) for 2hr, followed by LPS (0-1µg/ml) or P.
gingivalis [MOI 10:1] for 18hr. Figure 5, shows stats significant variation from
P. gingivalis above, however LPS also shows significant difference from all
points on the graph except for CBD1µg/ml, CBD 5µg/ml, negative control &
P.gingivalis (Figure 5A); P. gingivalis (Figure 5B).THC 1µg/ml, THC 5µg/ml
and P. gingivalis (Figure 5C). **/ *** p < 0.01 / 0.001, respectively, compared to
the P. gingivalis control.
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3.6 Pharmacological inhibition of CB2
THE CB2 INHIBITOR, JTE 907, FAILS TO RESCUE THE
PRODUCTIONOF IL-8 or IL-6 IN TIGK CELLS
We hypothesized that the anti-inflammatory effect of the cannabinoid
subtypes are mediated through epithelial CB2 receptors. In order to
confirm this hypothesis, we used a specific pharmacological inhibitor
of CB2, JTE90783, at a concentration of 5µg/ml. TIGK cells were
pretreated with JTE907 (5µg/ml) for 30min. Therefore, we next
determined the influence of marijuana derived cannabinoid subtypes
on the release of pro-inflammatory cytokine IL-8 and IL6 from P.
gingivalis-stimulated TIGK cells pretreated with JTE 907. As shown
in Figures 6 and 7, JTE907 failed to rescue IL-8 production in LPSor P. gingivalis stimulated TIGKs. Similarly, as shown in Figures 8
and 9, JTE907, failed to rescue IL-6 production in LPS- or P.
gingivalisstimulated TIGKs. These data imply that CB2 is not the
surface receptor responsible for cannabinoid initiated antiinflammatory signals in gingival epithelial cells.
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Figure 6A

Figure 7A

Figure 6B

Figure 7B

Figure6C

Figure 7C

FIGURES 6 and 7: Pretreatment with a specific CB2 inhibitor fails to rescue IL-8
release in P. gingivalis- and LPS -stimulated TIGK cells.
(A) CBD, (B) CBN or (C) THC, at the concentrations noted, suppressed IL-8
release in (Figure 9) LPS- and (Figure 10) P. gingivalis-stimulated TIGK cells. IL-8
production in TIGK cells pretreated with the CB2 inhibitor, JTE907 (5 µg/ml 30
mins), was also determined. TIGK cells were exposed to JTE-907 for 30 mins
followed by cannabinoid subtypes (1& 5 µg/ml) for 2hr and then to LPS (1µg/ml)
or P. gingivalis (MOI of 10:1) for 18hr. **/ *** p < 0.01 / 0.001, respectively,
compared to the LPS (Figure 9) or P. gingivalis only controls.
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Figure 8A

Figure 8B

Figure 8C

Figure 9B

Figure 9A

Figure 9C

FIGURES 8 and 9: Pretreatment with a specific CB2 inhibitor fails to rescue
IL-6 release in P. gingivalis- and LPS -stimulated TIGK cells.
(A) CBD, (B) CBN or (C) THC, at the concentrations noted, suppressed IL-6
release in (Figure 11) LPS- and (Figure 12) P. gingivalis-stimulated TIGK
cells. IL-6 production in TIGK cells pretreated with the CB2 inhibitor,
JTE907 (5 µg/ml 30 mins), was also determined. TIGK cells were exposed to
JTE-907 for 30 mins followed by cannabinoid subtypes (1& 5 µg/ml) for 2hr
and then to LPS (1µg/ml) or P. gingivalis (MOI of 10:1) for 18hr.*/**/ *** p
< 0.05 / 0.01 / 0.001, respectively, compared to the LPS (Figure 9) or P.
gingivalis only controls.
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3.7 The influence of cannabanoids on the growth of select oral pathogens
HIGH DOSES OF CANNABINOIDS SUPPRESS THE GROWTH
OF P.GINGIVALISAND F. ALOCIS BUT NOT T. DENTICOLA
To check the effect of cannabinoid subtypes on the viability of the
major representative oral periodontal pathogens like P. gingivalis, F.
alocis & T. denticola. We exposed these bacterial cultures to the
noted concentrations of the cannabinoid subtypes and plotted the
growth bacteria was grown in their respective culture medium. P.
gingivalis was grown in GAM supplemented, or not, with
cannabinoid subtypes cannabinol, cannbidiol and
tetrahydrocannabinol at concentrations of 0.1, 1, 5 & 10 µg/ml and
growth monitored by absorbance measurements at O.D. 600 nm. As
shown in Figure 10, higher doses of cannabinoids (CBD, CBN or
THC) inhibited the growth of P. gingivalis. Similar results were noted
for F. alocis (see Figure 11), wheras T.denticola was resistant to all
cannabinoid doses tested (see Figure 12).
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Figure 10A

Figure 10B

Figure 10 C
FIGURE 10: High dose cannabinoids suppress the growth of the
periodontal pathogen, P. gingivalis. P.gingivalis was grown in GAM
supplemented, or not, with (A) CBD, (B) CBN or (C) THC, at the
concentrations noted, and growth monitored by absorbance measurements at
O.D. 600 nm.*/**/ *** p < 0.05 / 0.01 / 0.001, respectively, compared to
control.
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Figure 11A

Figure 11B

Figure 11C

FIGURE 14: Cannabinoids do not influence to growth of T. denticola.
T. denticola

was grown in TYGVS medium supplemented, or not, with (A) CBD, (B)

CBN or (C) THC, at the

concentrations noted, and growth monitored by

absorbance measurements at O.D. 600 nm. There were no statistically significant
differences in the growth characteristics of cannabinoid -exposed and control bacteria
(all, p > 0.05 compared to the untreated control).
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Figure 12A

Figure 12B

Figure 12C

FIGURE 12: High dose cannabinoids suppress the growth of the periodontal
pathogen, F. alocis.
F. alocis

was grown in BHI supplemented, or not, with (A) CBD, (B) CBN or

(C) THC, at the concentrations noted, and growth monitored by absorbance
measurements at O.D. 600 nm.
*/ *** p < 0.05 / 0.001, respectively, compared to control
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CHAPTER 4 DISCUSSION
Cannabis use has been etiologically associated with periodontal
disease susceptibility, but the underlying mechanisms are unknown61,
62

. We have established that (i) high doses of marijuana derived

cannabinoids negatively influence the viability of TIGK cells; (ii)
sub-toxic doses of cannabinoids suppress pro-inflammatory cytokine
production by TIGK cells responding to LPS or to P. gingivalis; (iii)
sub-toxic doses of cannabinoids enhance anti-inflammatory IL-10
production by TIGK cells responding to LPS or to P. gingivalis; (iv) a
normal innate response to bacterial stimuli is not rescued by
pharmacological inhibition of CB2 in TIGK cells; and that (v) high
doses of cannabinoids inhibit the growth of P. gingivalis and F. alocis
but not T. denticola.
Should these five phenomena occur in the oral cavity of human
cannabis users, then we start to explain how marijuana, specifically
marijuana-derived cannabinoids, may predispose to chronic
periodontitis and/ or other periodontal diseases.
The oral epithelial barrier separates the host from the environment
and provides the first line of defense against pathogens, exogenous
substances and mechanical insults84. It consists of underlying
connective tissue and a stratified keratinized epithelium with at
membrane, whose cells undergo terminal differentiation resulting in
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the formation of a mechanically resistant surface. Gingival
keratinocytes are connected by various transmembrane proteins, such
as tight junctions, adherens junctions and gap junctions, each of
which has a specialized structure and specific functions84. Periodontal
pathogens are able to induce inflammatory responses that lead to
attachment loss and periodontal destruction. A number of studies
have demonstrated that the pathogenic oral bacteria influence the
expression and structural integrity of different cell-cell junctions37.
Tissue destruction can be mediated by host cells following
stimulation with cytokines and bacterial products75.To summarize, the
oral epithelium is able to react to a variety of exogenous, possibly
noxious influences.
Thus an intact oral epithelial barrier is a key component of the host
oral defense system. In consonance to the findings in our study, we
observe that the higher concentrations of marijuana derived
cannabinoid subtypes proved to have a negative effect on gingival
epithelial cell viability hence compromising the intactness of the
epithelial layer required for the initial host defense to periodontal
pathogens. It is possible that cannabinoid induced epithelial cell death
may compromise the integrity of this junctional epithelium layer,
facilitating breach by periodontal pathogens and, more importantly,
by bacterial-derived toxins known to contribute to the disease process
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in chronic periodontitis. This may explain the predisposition of
chronic periodontitis in marijuana users.
As we know, the etiology of periodontal diseases is bacterial. The
human oral cavity harbors an evolving load of microbial species. The
ecological interactions between the host and oral microbes determine
the severity of the disease process. The critical interplay between the
host immune mechanisms and inflammatory responses determine the
pathogenesis of complex diseases like chronic periodontitis70. The
immunological events seem to overlap during different phases of the
disease thus making the understanding of the pathogenesis of the
disease difficult.
The metabolic products of bacteria trigger junctional epithelium cells
to produce cytokines. The acute inflammation, is the physiologic
response to the microbial challenge to recruit adequate immune cells
to site of infection through the production of cytokines and
chemokines85, 86.Innate immunity is usually, characterized by the
phagocytosis and digestion of microorganisms and foreign substances
by macrophages and neutrophils86. Phagocytes such as macrophages
and neutrophils have surface receptors that recognize and bind
surface molecules of bacteria86. Thus these cytokines are seen to play
a protective role by helping to recruit immune cells to the site of the
inflammation87, 88. The host responds to microbial challenge by
generating an inflammatory cell infiltrate in the tissue subjacent to the
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periodontal pocket70.The cytokines and chemokines forms an integral
part of the initial innate immune response, they signal the submucosal
effector molecules leading to the activation of inflammatory signaling
pathways like NF-kB89. Cytokines are produced by resident cells,
such as epithelial cells and fibroblasts, and by phagocytes
(neutrophils and macrophages) in the acute and early chronic phases
of inflammation70.
The first cytokine identified to have chemotactic activity was
interleukin-8. In the periodontium, this cytokine is produced primarily
by gingival fibroblasts, gingival epithelial cells and endothelial
cells90. Interleukin-8 is a polymorphonuclear leukocyte
chemoattractant71. It is detectable in healthy and diseased periodontal
tissues and has been associated with subclinical inflammation of the
initial phase of the disease which is comprised of polymorphonuclear
neutrophil gradient along the intact junctional epithelium. Prior
studies have established that P. gingivalis evade and disrupt the host
immune homeostasis contributing to the exacerbation of the disease
process in chronic periodontitis91. It has also been established that P.
gingivalis produce gingipains a potent virulence factor which causes
inactivation of pro-inflammatory cytokine IL-892. This implies that
the periodontal pathogen survives longer evading the immune
response, contributing to polymicrobial dysbiosis of the periodontal
community17. Interleukin-6 is another pro-inflammatory cytokine
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which is one of the first few cytokines to appear in the periodontal
disease pathogenesis and is known to play an important part in the
progression of the chronic periodontitis. Interleukin-6 is an innate
cytokine which has been associated with inflammatory cell migration
and osteoclastogenesis in chronic periodontitis93.
In accordance to the prior studies, in our study we observe that the
marijuana derived cannabinoid subtypes abrogate production of proinflammatory cytokine IL-8 and IL-6 from LPS or P. gingivalis
stimulated TIGK cells. It may imply that the abrogation of these
cytokines would dysregulate the first line of innate immune response
in the epithelial cells. Cells pertaining to innate immunity like
neutrophils and macrophages would no longer be able infiltrate at the
site of inflammation. Hence the periodontal pathogen would be able
to survive for a longer period of time and secrete potent proteolytic
enzymes like proteases which would further accentuate the
destruction of the periodontium. The result of our study confirms the
well-established anti-inflammatory property of cannabinoids and how
it supports the suppression of the innate immune response explaining
the increasing susceptibility of marijuana users to chronic
periodontitis. Furthermore, suppression of inflammation, if it also
occurs in vivo, implies that clinicians may need to increase screening
vigilance in order to detect the onset of periodontal tissue destruction
in cannabis smokers with a suppression of clinical signs of
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inflammation with response down regulation of pro-inflammatory
cytokines.
The role of pro-inflammatory cytokines in the periodontal tissue
destruction is well documented in the animal model94. However,
cellular responses to the pro-inflammatory cytokines are regulated
negatively by anti-inflammatory cytokines and the balance between
these two categories of cytokine could be important in the outcome of
inflammatory response81. The prior studies showed that antiinflammatory cytokine IL-10 was suppressed by pro-inflammatory
cytokine in chronic periodontitis95. The studies also showed that the
difference of pro and anti-inflammatory cytokine (IL-10) in
periodontitis was very subtle but significant to cause destruction of
the periodontal structures in chronic periodontitis81. It was noted in
our study that there was concomitant rise in the expression of antiinflammatory cytokine IL-10 from LPS/ P. gingivalis stimulated
TIGK cells when exposed to marijuana derived cannabinoid subtypes
at sub-lethal doses. The findings of our study does not seem to be in
accordance to the prior studies .The elevated levels of IL-10 on
exposure to cannabinoids in epithelial cells implies that marijuana
derived cannabinoids although are implicated as a risk factor for
chronic periodontitis they suppress pro-inflammatory cytokine and
increases the anti-inflammatory ones which is opposite to the pattern
usually observed in earlier studies involving chronic periodontitis95.It
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is possible that cannabinoid induced suppression of pro–inflammatory
cytokines may prevent the recruitment of immune cells like
neutrophils which is a spontaneous reaction of the innate immune
mechanism and up regulation of IL-10 further contributes in
suppressing the pro-inflammatory cytokines(cellular crosstalk)
preventing the initial innate inflammatory response. Thus helping the
disease associated pathogen to evade the immune response. As
cannabinoids are known to be anti-inflammatory it is possible that it
plays a role in upregulating the expression of anti-inflammatory
cytokine IL-10. It has been shown in prior studies that IL-10 and
cannabinoids have an osteo-protective effect82, 96.Therefore it is
necessary to research further in this direction to gain a mechanistic
insight that would explain the osteo-protective influence of
cannabinoid subtypes in context to its anti-inflammatory property in
chronic periodontitis model.
It has been noted previously that CB2 is expressed in the gingival
epithelial cells comprising the junctional epithelium59, 60. We had
hypothesized that the anti-inflammatory actions of cannabinoids may
be mediated through such surface CB2 receptors. It was noted that
pharmacological inhibition of CB2 receptor did not rescue the innate
immune response to bacterial stimulants in epithelial cells. Further
research would be needed to understand the functional importance of
the CB2 receptor. Other specific inhibitor like AM630, along with

57

siRNA-mediated CB2 gene silencing, could be used to determine the
importance of CB2 in cannabinoid-mediated suppression of the innate
response to dental plaque pathogens in hum an gingival epithelial
cells. CB2 expression could be also studied using q PCR telling us
more about the m-RNA levels.
It is also possible that the JTE907 results are genuine, therefore the
anti-inflammatory action of cannabinoids may be brought about by
other non-CB2 target receptors. Therefore creating a scope of
studying other potential target receptors like the CB1, GPR55 and
A2A receptors which may be associated with the anti-inflammatory
function of marijuana derived cannabinoids97, 98.
Finally, the findings that P. gingivalis and F. alocis, but not T.
denticola, are susceptible to cannabinoids is both novel and
intriguing. Essentially, clinically healthy periodontal tissue maintains
a highly ordered, mild state of inflammation70. It is usually
established that the normal oral microflora, which is thought to
provide the stimulus for this mild inflammatory response. However,
the highly ordered state of mild inflammation is replaced by a
disordered state of severe inflammation with the altered microbial
community14. As seen that suppression and negative influence of
marijuana derived cannabinoid subtypes on periodontal pathogen P.
gingivalis and F.alocis seem to alter the periodontal microbial
community. Thus, it is proposed that the shift from a symbiotic
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microflora to a dysbiotic pathogenic community triggers the potent
host inflammatory response that contributes to the tissue destruction
and alveolar bone loss that are characteristic of periodontitis17.
There are a number of limitations to this study. It is possible that
cytokine release in response to E. coli LPS, used as a positive control
in much of the experiments herein, may have been optimized with the
addition of serum as soluble CD14 is present in serum and facilitates
binding of LPS .Binding of LPS to CD14 is enhanced by the presence
of the LPS binding protein (LBP)99.LBP may also enhance binding of
whole Gram-negative bacteria to cells thus transferring LPS to a
second receptor that directly transduces the signal thus or by the use
of protease inhibitors, that would stabilize cytokines produced.
Further, we did not monitor the activity of cytokine-encoding genes.
In the future, further research could be carried out to analyze the
complex signaling pathways associated in cannabinoid-induced
suppression of innate immunity in epithelial cells. The information
generated would be further used in gingival epithelial cells, other
innate cell types, and additional pathogen strains as well as the
establishment of in vivo relevance in mouse models of periodontitis
and inflammation.
In summary, cannabinoids exert multiple negative effects on
epithelial viability, on epithelial responses to bacterial stimuli and on
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bacterial growth characteristics. In concert, these events are likely to
predispose individuals who smoke marijuana to periodontal diseases.
Further delineation of marijuana-periodontal disease interactions may
be warranted. Determination of the amount of cannabinoids found in
the gingival crevice of cannabis users; the mechanisms of
cannabinoid induced epithelial death; the signaling pathways
controlling innate immune suppression; and the influence of cannabis
intake on the periodontal microbiome are all likely to provide useful
information helping to explain how marijuana induces and/or
exacerbates periodontal diseases. Such insights are needed for the
development of novel therapeutic and preventive approaches for this
growing section of American society.
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